Transcriptional adaptation of Mycobacterium ulcerans in an original mouse model: New insights into the regulation of mycolactone

Autor: Marie Robbe-Saule, Mélanie Foulon, Isabelle Poncin, Lucille Esnault, Hugo Varet, Rachel Legendre, Alban Besnard, Anna E. Grzegorzewicz, Mary Jackson, Stéphane Canaan, Laurent Marsollier, Estelle Marion

Publikováno v: Virulence, Vol 12, Iss 1, Pp 1438-1451 (2021)

Mycobacterium ulcerans is the causal agent of Buruli ulcer, a chronic infectious disease and the third most common mycobacterial disease worldwide. Without early treatment, M. ulcerans provokes massive skin ulcers, caused by the mycolactone toxin, it

Externí odkaz: https://doaj.org/article/1cb69814d64d40b389c32a0800f06a86

The key factors contributing to the risk, diagnosis and treatment of non-tuberculous mycobacterial opportunistic infections

Autor: Anna E. Grzegorzewicz, Mariola Paściak

Publikováno v: Postępy Higieny i Medycyny Doświadczalnej. 75:696-710

The incidence and prevalence of diseases caused by non-tuberculous mycobacteria (NTM) have been steadily increasing worldwide. NTM are environmental saprophytic organisms; however, a few strains are known to produce diseases in humans affecting pulmo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53690a63ad747e6de0556c656c9db348
https://doi.org/10.2478/ahem-2021-0050

A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis

Autor: Antonio Peixoto, Monika Záhorszká, Jana Korduláková, Mathieu Danel, Fernanda Goncalves, Elodie Vega, Asma Farjallah, Maria Rosalia Pasca, Mary Jackson, Giulia Degiacomi, Laurent R. Chiarelli, Cendrine Seguin, Martin Forbak, Christian Lherbet, Stefan Chassaing, Chantal Carayon, Souhir Abid, Marco Fumagalli, Anna E. Grzegorzewicz

Publikováno v: ACS Infectious Diseases
ACS Infectious Diseases, American Chemical Society, 2021, 7 (3), pp.552-565. ⟨10.1021/acsinfecdis.0c00325⟩
ACS Infectious Diseases, 2021, 7 (3), pp.552-565. ⟨10.1021/acsinfecdis.0c00325⟩

International audience; A novel coumarin-based molecule, designed as a fluorescent surrogate of a thiacetazone-derived antitubercular agent, was quickly and easily synthesized from readily available starting materials. This small molecule, coined Cou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5b5cd98cba63d79872ca55f29014c7
https://hal.archives-ouvertes.fr/hal-03209886/document

Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System

Autor: Richard E. Lee, Bhanupriya Angala, Jiuyu Liu, Joël Lelièvre, Michael R. McNeil, Mary Jackson, Anna E. Grzegorzewicz, Jorge Esquivias

Publikováno v: Antimicrob Agents Chemother

Phenotypic screening of inhibitors of the essential Mycobacterium tuberculosis FAS-II dehydratase HadAB led to the identification of GSK3011724A, a compound previously reported to inhibit the condensation step of FAS-II. Whole-cell-based and cell-fre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee3a28f645c30f0a8905e3540bd92a8
https://doi.org/10.1128/aac.01914-20

Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone

Autor: Alyssa Margolis, E. Jeffrey North, Victoria Jones, Annaïk Quémard, Jared J. Lindenberger, Donald R. Ronning, Richard E. Lee, Michael R. McNeil, Anna E. Grzegorzewicz, Mary Jackson, Patrick J. Brennan, Jana Korduláková, Nathalie Eynard

Publikováno v: ACS Infectious Diseases. 1:91-97

Isoxyl and Thiacetazone are two antitubercular prodrugs formerly used in the clinical treatment of tuberculosis. Although both prodrugs have recently been shown to kill Mycobacterium tuberculosis through the inhibition of the dehydration step of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe8c0f78a0756c8b8e30f41e463ad456
https://doi.org/10.1021/id500032q